Morgan Stanley Keeps Their Buy Rating on Ventyx Biosciences (VTYX)

TipRanks

Mar. 19, 2023, 07:55 PM

In a report released yesterday, Matthew Harrison from Morgan Stanley maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $45.00. The company’s shares closed last Friday at $36.67.

According to TipRanks, Harrison is a 5-star analyst with an average return of 6.6% and a 51.22% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Seagen, Regeneron, and Moderna.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ventyx Biosciences with a $54.38 average price target.

See today’s best-performing stocks on TipRanks >>

VTYX market cap is currently $2.08B and has a P/E ratio of -20.54.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VTYX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Read More on VTYX: